Contributions of the Framingham Heart Study to the epidemiology of coronary heart disease

JAMA Cardiology

Volumn 1, Issue 7, 2016, Pages 825-830

  Chen, George ^a,b   Levy, Daniel ^a,b,c  

^a FRAMINGHAM HEART STUDY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; MESSENGER RNA; MICRORNA;

CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FRAMINGHAM RISK SCORE; GENE EXPRESSION; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PRIORITY JOURNAL; PROTEOMICS; REVIEW; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LONGITUDINAL STUDY; RISK FACTOR;

CORONARY DISEASE; EPIDEMIOLOGIC STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LONGITUDINAL STUDIES; RISK FACTORS; STROKE;

EID: 85037114234     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.2050     Document Type: Review

References (49)

1. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279-281.
2. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med. 1975;4(4): 518-525.
3. Splansky GL, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165(11):1328-1335.
4. Cupples LA, Arruda HT, Benjamin EJ, et al. The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet. 2007;8(suppl 1):S1.
5. National Heart, Lung, and Blood Institute. SHARe: SNP Health Association Resource. http://www.nhlbi.nih.gov/research/resources/genetics -genomics/share. Updated September 2011. Accessed March 1, 2016.
6. Oppenheimer GM. Becoming the Framingham Study 1947-1950. Am J Public Health. 2005;95(4): 602-610.
7. Minutes MF. October 14-15, 1949. Located at: Records of the National Institutes of Health, National Advisory Heart Council, Box 21, National Archives, College Park, MD.
8. Wong ND, Levy D. Legacy of the Framingham Heart Study: rationale, design, initial findings, and implications. Glob Heart. 2013;8(1):3-9.
9. Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham Study. Am J Public Health Nations Health. 1957;47(4, pt 2):4-24.
10. Dawber TR, Kannel WB, Revotskie N, Stokes J III, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease: six years’ follow-up experience in the Framingham Study. Am J Public Health Nations Health. 1959;49: 1349-1356.
11. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease—six-year follow-up experience: the Framingham Study. Ann Intern Med. 1961;55:33-50.
12. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202(11):1028-1034.
13. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
14. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
15. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
16. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38(1):46-51.
17. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1, pt 2):293-298.
18. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
19. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153(2):154-183.
20. National Cholesterol Education Program. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89(3):1333-1445.
21. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286(2):180-187.
22. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25)(suppl 2):S49-S73.
23. Lloyd-Jones DM, Wilson PW, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004; 94(1):20-24.
24. Pencina MJ, D’Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119(24):3078-3084.
25. Cupples LA, D’Agostino RB, Anderson K, Kannel WB. Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med. 1988;7(1-2):205-222.
26. Kannel WB, Wolf PA, Garrison RJ. Monograph Section 34: Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements: Framingham Heart Study, 30-Year Follow-Up. Springfield, MA: National Technical Information Service; 1987:1-459.
27. D’Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2, pt 1):272-281.
28. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med. 1969;71(1):89-105.
29. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med. 1970;72(6):813-822.
30. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med. 1983;75(3A):4-11.
31. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81(3):815-820.
32. Feigenbaum H. Evolution of echocardiography. Circulation. 1996;93(7):1321-1327.
33. Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987;59(9):956-960.
34. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med. 1989;110 (2):101-107.
35. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561-1566.
36. Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, McNamara PM. Blood pressure aggregation in families. Am J Epidemiol. 1979;110 (3):304-312.
37. Garrison RJ, Castelli WP, Feinleib M, et al. The association of total cholesterol, triglycerides and plasma lipoprotein cholesterol levels in first degree relatives and spouse pairs. Am J Epidemiol. 1979;110(3):313-321.
38. Chesebro JH, Fuster V, Elveback LR, Frye RL. Strong family history and cigarette smoking as risk factors of coronary artery disease in young adults. Br Heart J. 1982;47(1):78-83.
39. Schildkraut JM, Myers RH, Cupples LA, Kiely DK, Kannel WB. Coronary risk associated with age and sex of parental heart disease in the Framingham Study. Am J Cardiol. 1989;64(10): 555-559.
40. Larson MG, Atwood LD, Benjamin EJ, et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet. 2007;8(suppl 1):S5.
41. Psaty BM, O’Donnell CJ, Gudnason V, et al; CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2(1):73-80.
42. Ehret GB, Munroe PB, Rice KM, et al; International Consortium for Blood Pressure Genome-Wide Association Studies; CARDIoGRAM consortium; CKDGen Consortium; KidneyGen Consortium; EchoGen consortium; CHARGE-HF consortium. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103-109.
43. Schunkert H, König IR, Kathiresan S, et al; Cardiogenics; CARDIoGRAM Consortium. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333-338.
44. Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010; 466(7307):714-719.
45. Huan T, Zhang B, Wang Z, et al; Coronary ARteryDIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) Consortium, International Consortium for Blood Pressure GWAS (ICBP). A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(6):1427-1434.
46. Joehanes R, Ying S, Huan T, et al. Gene expression signatures of coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(6):1418-1426.
47. Huan T, Rong J, Tanriverdi K, et al. Dissecting the roles of microRNAs in coronary heart disease via integrative genomic analyses. Arterioscler Thromb Vasc Biol. 2015;35(4):1011-1021.
48. Yao C, Chen BH, Joehanes R, et al. Integromic analysis of genetic variation and gene expression identifies networks for cardiovascular disease phenotypes. Circulation. 2015;131(6):536-549.
49. Whitman IR, Pletcher MJ, Vittinghoff E, et al. Perceptions, information sources, and behavior regarding alcohol and heart health. Am J Cardiol. 2015;116(4):642-646.